AP2014007650A0 - Inhibition of viral gene expression - Google Patents

Inhibition of viral gene expression

Info

Publication number
AP2014007650A0
AP2014007650A0 AP2014007650A AP2014007650A AP2014007650A0 AP 2014007650 A0 AP2014007650 A0 AP 2014007650A0 AP 2014007650 A AP2014007650 A AP 2014007650A AP 2014007650 A AP2014007650 A AP 2014007650A AP 2014007650 A0 AP2014007650 A0 AP 2014007650A0
Authority
AP
ARIPO
Prior art keywords
inhibition
gene expression
viral gene
viral
expression
Prior art date
Application number
AP2014007650A
Other languages
English (en)
Inventor
Justin Hean
Abdullah Ely
Musa Marimani
Original Assignee
Goethe University
Univ Witwatersrand Jhb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goethe University, Univ Witwatersrand Jhb filed Critical Goethe University
Publication of AP2014007650A0 publication Critical patent/AP2014007650A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3527—Other alkyl chain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AP2014007650A 2011-10-28 2012-10-26 Inhibition of viral gene expression AP2014007650A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA201107890 2011-10-28
PCT/IB2012/055915 WO2013061295A1 (en) 2011-10-28 2012-10-26 Inhibition of viral gene expression

Publications (1)

Publication Number Publication Date
AP2014007650A0 true AP2014007650A0 (en) 2014-05-31

Family

ID=47326248

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2014007650A AP2014007650A0 (en) 2011-10-28 2012-10-26 Inhibition of viral gene expression

Country Status (9)

Country Link
US (1) US20140350080A1 (cs)
EP (1) EP2771466A1 (cs)
CN (1) CN104011209A (cs)
AP (1) AP2014007650A0 (cs)
BR (1) BR112014010134A2 (cs)
CA (1) CA2853609A1 (cs)
IN (1) IN2014CN03921A (cs)
RU (1) RU2014121304A (cs)
WO (1) WO2013061295A1 (cs)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2877644A1 (en) 2012-07-03 2014-01-09 Prosensa Technologies B.V. Oligonucleotide for the treatment of muscular dystrophy patients
EP3315608B1 (en) * 2015-06-26 2020-09-16 Suzhou Ribo Life Science Co., Ltd. Sirna, pharmaceutical composition and conjugate which contain sirna, and uses thereof
US20170137821A1 (en) 2015-07-17 2017-05-18 Arcturus Therapeutics, Inc. Molecules and agents for treating hepatitis b virus
US20170016000A1 (en) 2015-07-17 2017-01-19 Arcturus Therapeutics, Inc. Compositions and agents against hepatitis b virus and uses thereof
US11208429B2 (en) 2017-06-16 2021-12-28 Eisai R&D Management Co., Ltd. Modified nucleic acid monomer compound and oligonucleic acid analog
AU2018377716B2 (en) * 2017-12-01 2024-12-19 Suzhou Ribo Life Science Co., Ltd Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
WO2020087107A1 (en) * 2018-10-31 2020-05-07 The University Of Sydney Compositions and methods for treating viral infections

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1814614A (zh) * 2005-02-06 2006-08-09 中国人民解放军军事医学科学院毒物药物研究所 核酸、肽核酸衍生物及它们的用途
US20100209491A1 (en) * 2007-09-17 2010-08-19 Mogam Biotechnology Research Institute Method for enhancing serum stability and lowering immune response of sirna down-regulating gene expression of hbv or hcv

Also Published As

Publication number Publication date
RU2014121304A (ru) 2015-12-10
US20140350080A1 (en) 2014-11-27
EP2771466A1 (en) 2014-09-03
BR112014010134A2 (pt) 2019-09-24
IN2014CN03921A (cs) 2015-09-04
CN104011209A (zh) 2014-08-27
CA2853609A1 (en) 2013-05-02
WO2013061295A1 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
IL269662A (en) Hepatitis C virus inhibitors
PH12013501969A1 (en) Compositions and methods for inhibiting expression of tmprss6 gene
EP2677865A4 (en) BROMODOMAIN INHIBITORS AS MODULATORS OF GENE EXPRESSION
GB201116559D0 (en) Novel viral replication inhibitors
IL233081A (en) History of Batolin
ZA201403995B (en) Stereoselective total synthesis of noribogaine
GB201110647D0 (en) Delivery of viral agents
BR112014007029A2 (pt) métodos aperfeiçoados de terapia gênica
SG11201400102WA (en) Inhibitors of nedd8-activating enzyme
ZA201504442B (en) Regulation of gene expression
EP2791102A4 (en) PROPENOATE DERIVATIVES OF BETULIN
AP2014007650A0 (en) Inhibition of viral gene expression
GB201410312D0 (en) Photobioreactor
GB201117482D0 (en) Targetiing of miRNA precursors
IL232848A0 (en) Human gene derived promoter
ZA201307229B (en) Prodrugs of d-isoglutamyl-[d/l]- tryprophan
EP2768941A4 (en) photobioreactor
EP2739738A4 (en) USE OF INTEGRASE FOR TARGETED GENE EXPRESSION
EP2663657A4 (en) GENOMIC ASSEMBLY
AU2012902347A0 (en) Inhibition of small RNA activity
GB201114748D0 (en) Enzyme inhibition
GB201114751D0 (en) Enzyme inhibition
GB201114891D0 (en) Novel viral replication inhibitors
GB201114710D0 (en) Treatment of hepatitis c